May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden Opposes Trump and Senate Republicans' Big Bad Bill Ahead of the Vote
- Wyden Blasts Budget Fakery as Republicans Go Nuclear
- Wyden Statement on Latest Parliamentarian Guidance
- Wyden Statement on New CBO Numbers Showing More than $930 Billion in Medicaid Cuts In New Senate Draft
- Wyden Blasts Republican “Death Sentence” for American Clean Energy, Warns of Imminent Utility Bill Hike